Furthermore, when the CUG-BP1 up-regulation is inhibited by the specific shRNA in denervation-induced muscle atrophy, muscle atrophy process was strikingly prevented, which suggests that CUG-BP1 is a potential therapeutic target in the treatment of skeletal muscle atrophy. This evidence concerns the gene CELF1 and muscular atrophy.